FDA approves Orexo’s Zubsolv as opioid dependence maintenance therapy
Indicated for use as part of a complete treatment plan, including counseling and psychosocial support, the once-daily, sublingual tablet is an advanced formulation of buprenorphine and naloxone. Expected
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.